

60E

27 October 2008

DSM reports strong Q3 against deteriorating market conditions

- Continued strong organic sales growth (12%), driven by pricing power.
- Sustained strong profitability in Nutrition.
- Accelerating economic downturn increasingly visible in Materials Sciences.
- EBIT from continuing operations up 27% to EUR 267 million; EPS up 41%.
- 2008 operating profit expected to be around EUR 1,000 million.

Commenting on the results, Feike Sijbesma, chairman of the DSM Managing Board, said: *"DSM has reported a strong third quarter result and the company remains on track to achieve a record operating profit in 2008. Nutrition profitability remains strong. DSM Agro benefited from favorable market conditions. DSM's Materials Sciences businesses also performed relatively well during Q3 but are facing more impact from the deteriorating economic conditions in the last few weeks, from which of course nobody is immune.*

"Looking out towards the remainder of the year, it is apparent that the crisis in the financial markets has started to impact the real economy, leading to significantly lower customer demand in some areas. Some end markets will be more resilient than others, which is one of the main reasons for DSM's strategic shift to Life Sciences and Materials Sciences. DSM is conservatively financed and appropriate steps are being implemented to prepare for more difficult market conditions. We, however, remain fully committed to our innovation and growth ambitions."

third quarter			in EUR million	January – September		
2008	2007	+/-		2008	2007	+/-
Continuing operations:						
2,363	2,163	+9%	<u>Net sales</u>	7,124	6,464	+10%
393	315	+25%	Operating profit before depreciation and amortization (EBITDA)	1,111	943	+18%
267	210	+27%	<u>Operating profit (EBIT)</u>	779	634	+23%
104	68	+53%	- Nutrition	292	204	+43%
22	35	-37%	- Pharma	59	73	-19%
62	73	-15%	- Performance Materials	212	221	-4%
19	21	-10%	- Polymer Intermediates	85	73	+16%
102	36	+183%	- Base Chemicals and Materials	215	116	+85%
-42	-23		- Other activities	-84	-53	
Discontinued operations (DSM Special Products):						
29	24		Net sales	82	67	
2	6		Operating profit before depreciation and amortization (EBITDA)	5	4	
2	4		Operating profit (EBIT)	4	-1	
Total DSM:						
2,392	2,187	+9%	<u>Net sales</u>	7,206	6,531	+10%
269	214	+26%	<u>Operating profit (EBIT)</u>	783	633	+24%
182	142	+28%	<u>Net profit before exceptional items</u>	537	428	+25%
-	-		Net result from exceptional items	-	-111	
182	142	+28%	<u>Net profit</u>	537	317	+69%
Net earnings per ordinary share in EUR:						
1.10	0.78	+41%	- before exceptional items, continuing operations	3.20	2.33	+37%
1.10	0.78	+41%	- including exceptional items, continuing operations	3.20	1.72	+86%
1.11	0.80	+39%	- including exceptional items, total DSM	3.21	1.71	+88%

In this report:

- 'operating profit' (before depreciation and amortization) is understood to be operating profit (before depreciation and amortization) before exceptional items.
- 'net profit' is the net profit attributable to equity holders of Royal DSM N.V.
- 'continuing operations' refers to the DSM operations excluding DSM Special Products.

Overview

DSM's operating profit from continuing operations in Q3 (EUR 267 million) was only slightly below the result in the second quarter, which was DSM's best ever quarter, and 27% better than the comparable quarter in last year. The main drivers behind this strength were the performance of the Nutrition cluster and continued high fertilizer prices. However, DSM's Performance Materials and Polymer Intermediates clusters and some businesses in Base Chemicals & Materials increasingly experienced economic weakness, particularly towards the end of the quarter, due to their exposure to more affected end markets, such as automotive, building and construction, coatings and electrics and electronics.

In Nutrition, DSM's focus on differentiation and innovation in combination with structural changes in the vitamins industry has resulted in significantly higher prices and profitability. Volume growth in Nutrition was restrained in Q3, reflecting DSM's policy to prioritize value over volume, together with a certain amount of general de-stocking in the industry during the quarter.

Performance Materials, Polymer Intermediates and some parts of Base Chemicals and Materials are being faced with a softening demand. This is a reflection of the weakening of the worldwide economy, which is currently being amplified by a de-stocking in the downstream industry. In Performance Materials the excellent performance in DSM Dyneema is partly compensating for weakness in other parts of the cluster.

Net sales

<i>in EUR million</i>	third quarter		differ- ence	vol- umes	prices	exch. rates	other
	2008	2007					
Nutrition	666	579	15%	-3%	22%	-6%	2%
Pharma	203	242	-16%	-10%	-3%	-3%	-
Performance Materials	580	591	-2%	-2%	2%	-2%	-
Polymer Intermediates	335	295	14%	3%	16%	-5%	-
Base Chemicals and Materials	457	349	31%	-7%	39%	-2%	1%
Other activities	122	107					
Total, continuing operations	2,363	2,163	9%	-3%	15%	-4%	1%
Discontinued operations	29	24					
Total	2,392	2,187					

Net sales from DSM's continuing operations increased by 9% in the third quarter. Organic sales growth continued to be very strong at 12%, where price management prevailed over volume. Exchange rates had on balance a negative effect of 4%, mainly caused by a 12% lower US dollar.

Operating profit

The operating profit from continuing operations amounted to EUR 267 million, an increase of 27% on the comparative period last year. This performance was achieved despite higher feedstock and energy costs of approximately EUR 170 million and much lower currency exchange rates versus the Euro, which had an effect on the operating profit of some EUR 15 million (after hedging). All of this was more than compensated for by the substantial organic growth in Nutrition and DSM Agro.

Business review by cluster

Nutrition

third quarter		<i>in EUR million</i>	January - September	
2008	2007		2008	2007
666	579	Net sales	2,007	1,702
144	100	Operating profit before depreciation and amortization	396	298
104	68	Operating profit	292	204

Nutrition is clearly benefiting from its successful differentiation and innovation strategy in vitamins, which is being amplified by the changing dynamics in the industry. During the quarter there was reduction of previously increased safety stocks by some customers. Organic sales growth was 19%, benefiting from the strategy to focus on value over volume.

Prices for vitamins A, E and C could be increased further in Q3. DSM Nutritional Products' operating profit increased strongly as a result of these price increases despite the negative impact of the US dollar, higher feedstock and energy costs and the phasing-out of some Roche contracts.

The operating profit of DSM Food Specialties was somewhat below last year's because of lower currencies, higher energy prices and a slightly weaker demand.

Pharma

third quarter		<i>in EUR million</i>	January - September	
2008	2007		2008	2007
203	242	Net sales	647	669
37	59	Operating profit before depreciation and amortization	105	135
22	35	Operating profit	59	73

Net sales and operating profit were below Q3 2007.

DSM Pharmaceutical Products is entering a weaker phase in its business following the expiration of some large contracts (including the phasing-out of some Roche contracts) before it has been able to start up new custom manufacturing contracts. In DSM Anti-Infectives, prices are clearly below the peak seen in last year's rally, but remain at an acceptable level.

Performance Materials

third quarter		<i>in EUR million</i>	January - September	
2008	2007		2008	2007
580	591	Net sales	1,805	1,792
84	92	Operating profit before depreciation and amortization	275	280
62	73	Operating profit	212	221

Some parts of DSM Performance Materials experienced economic headwinds, particularly those exposed to volatile end markets. This resulted in flat organic sales.

Due to the weakening market conditions and adverse currency exchange rate developments, operating profit was lower at DSM Engineering Plastics and DSM Resins. This was partly compensated for by the continuing strong growth at DSM Dyneema. Despite the more difficult market conditions, the composition of the cluster's product portfolio and the strength of its businesses are creating relative resilience in Performance Materials.

Polymer Intermediates

third quarter		<i>in EUR million</i>	January - September	
2008	2007		2008	2007
335	295	Net sales	1,003	909
27	27	Operating profit before depreciation and amortization	105	91
19	21	Operating profit	85	73

The higher sales volumes during the quarter at Polymer Intermediates were driven by the expanded production capacity for acrylonitrile as well as solid demand. Prices for both caprolactam and acrylonitrile were clearly higher than last year, leading to a very solid 19% organic growth.

However, it became clear during the quarter that the caprolactam business is starting to face more difficult market conditions. The caprolactam business in the United States, but also in other regions including China, saw demand weaken in combination with customer de-stocking in anticipation of lower prices following the drop in oil prices.

Operating profits and margins came under pressure towards the end of the quarter due to slow demand, higher feedstock costs and the drop in caprolactam prices.

Base Chemicals and Materials

third quarter		in EUR million	January – September	
2008	2007		2008	2007
457	349	Net sales	1,298	1,073
122	51	Operating profit before depreciation and amortization	271	165
102	36	Operating profit	215	116

Organic sales growth for Base Chemicals and Materials was 32% because of higher prices and despite lower sales volumes, mostly due to the lower product availability at DSM Agro as a result of the ammonia outage.

DSM Agro in particular contributed to the higher operating profit. DSM Agro’s fertilizer market in Europe continued to be very tight in Q3, which was reflected in substantially higher prices. The other business groups performed at an equal or better level than in last year.

Other activities

third quarter		in EUR million	January - September	
2008	2007		2008	2007
122	107	Net sales	364	319
-21	-14	Operating profit before depreciation and amortization	-41	-26
-42	-23	Operating profit	-84	-53

The net sales growth is mainly attributable to the acquisition of Polymer Technology Group. The strong decrease in operating result can be fully attributed to the costs of the ammonia outage, which are covered by the captive insurance company.

Net profit

Net profit before exceptional items increased from EUR 142 million in Q3 2007 to EUR 182 million (+28%).

Earnings per share (continuing operations, before exceptional items) increased to EUR 1.10 per ordinary share (+41%) due to the higher net profit and the share buy-back.

Net finance costs amounted to EUR 26 million, which is EUR 5 million higher than last year. This is mainly caused by the higher net debt.

The effective tax rate was 25%, the same as last year.

Cash flow, capital expenditure and financing

Cash flow from operating activities amounted to EUR 518 million in the year to date. Cash flow was negatively affected by a strong increase in operating working capital.

Capital expenditure in Q3 amounted to EUR 128 million. The year-to-date capital expenditure amounted to EUR 376 million which is clearly higher than last year (EUR 291 million).

Compared to year-end 2007 net debt increased by EUR 549 million to EUR 1,887 million due to the share buy-back programme and the increase in working capital. This represents a gearing level of 26%.

Workforce

The workforce increased overall by 798 from year-end 2007 to 24,052 at the end of Q3 2008. This was due to acquisitions (+320) and capacity expansions (+478).

Progress update on DSM Strategy Vision 2010

DSM's acceleration of the strategic program *Vision 2010 – Building on Strengths*, announced in September 2007, focuses on delivering faster growth, higher margins and improved earnings quality from the company's portfolio. The strategy will see the transformation of DSM into a Life Sciences and Materials Sciences company capable of sustainable growth.

The key drivers – market-driven growth and innovation, increased presence in emerging economies and operational excellence – remain at the heart of DSM's strategy.

In Q3 DSM announced the acquisition of the business and substantially all of the assets of Valley Research, Inc. (USA) to reinforce its leading global position in food enzymes. The acquisition has been completed. Also, two venturing investments were announced during the quarter.

A number of investments aimed at future profitable growth were announced during the quarter, such as an expansion worth EUR 10 million by DSM NeoResins+ of the waterborne polyurethane capacity in Spain, a 50% expansion of the product capacity for [®]claryl picture glass and the first dedicated line for manufacturing Dyneema Purity[®] fiber in Greenville (United States).

DSM also announced that under phase 1 of the investment program for DSM Dyneema, expected to involve up to USD 450 million over the next 2-3 years, projects have been approved to build additional capacity for UD (UniDirectional) and fiber at DSM Dyneema's Greenville facility.

With the opening of the second Stanyl[®] plant in Geleen (Netherlands) in September, worldwide production capacity for this high-performance plastic has doubled.

In Q3 2008 sales in China amounted to USD 288 million, which represents an increase of 32% relative to the comparable period of last year (first nine months 2008: USD 918 million being an increase of 34%).

In China, DSM Engineering Plastics inaugurated its new Akulon[®] PA6 polymerization plant. DSM also announced during the quarter the closure of its citric acid manufacturing plant in Wuxi (China) by Q1 2009.

As a result of the accelerated shift towards Life Sciences and Materials Sciences, DSM announced that a number of businesses which do not fit in with the accelerated strategy will be carved out and divested. The divestment process for Agro and Melamine, Elastomers and Urea Licensing has commenced in the form of a controlled auction process and the divestments are expected to be completed within the timeframe of *Vision 2010*, as planned.

In the area of sustainability, DSM Powder Coating Resins launched a new technology platform for corrosion protective coatings. The technology offers the possibility to significantly reduce and sometimes completely eliminate chemical pre-treatment steps. DSM Composite Resins won the environment prize at the AVK Innovation Awards for Palapreg Premium[®], a new resins system for use in automotive exterior applications.

DSM Nutritional Products and the United Nations World Food Programme (WFP) won the ICIS Innovation Award for Best Business Innovation for the MixMe[™] micronutrient powder.

During the quarter, DSM announced and introduced many new innovations. The highlights can be found in an appendix to this press release.

Actions addressing the economic downturn

The credit crunch and recent financial crisis are beginning to affect the real economy and markets around the world are facing an economic slowdown. Some areas particularly exposed to weakening consumer spending, such as building and construction, automotive and electrics & electronics, face significantly more difficult business conditions, especially in the US and large parts of Europe. A continuation of the current business conditions is expected to impact DSM due to the presence of certain parts of its business in these more exposed end markets.

Due to its accelerated focus on Life Sciences and Materials Sciences, DSM expects that more than half of its portfolio will be less sensitive to an economic downturn (Nutrition, Pharma, DSM Dyneema and parts of Base Chemicals and Materials). The other businesses in Materials Sciences have a strong focus on the higher added value part of the business and should show relative resilience, although this will be difficult to fully maintain in the current economic context, because of the unprecedented intensity with which some end-markets are reacting at the moment. Other developments such as a stronger dollar and lower oil prices resulting in reduced energy costs will have a positive effect on DSM's results. DSM is confident that its operational excellence in all business processes will be the basis for a strong competitive position in the current market conditions.

The financial crisis has both substantially restricted the availability and increased the pricing of credit. In view of the situation in the global credit markets, DSM postponed the third stage of its EUR 750 million share buy-back program in April 2008 and has continued to employ a conservative financing policy with a healthy long term funding plan in place. The majority of the company's long term debt matures after 2012 and in September DSM successfully increased its outstanding EUR 300 million 4.00% bond due 2015 by a further EUR 200 million. DSM has adequate short term financing opportunities and an increase in interest rates will only have a limited effect on DSM's results. DSM's pension plans are solidly funded and although the current pension

funding position has declined, it is not expected that additional cash contributions will be required (although a non-cash negative EBIT effect in 2009 is expected).

To mitigate the effects of a continuation of the slowdown, a number of actions have been implemented to improve cash flow. Inventories are being reduced by temporary plant shut downs. Tight credit risk management and credit control has been put in place for accounts receivable to prevent increasing payment terms and insolvency losses.

In addition, with clear evidence that the credit crunch is now spreading to the real economy, steps are also being taken to preserve profitability, such as tighter cost control. DSM's innovation programs, however, will be unaffected by these measures to capture growth opportunities even in difficult times.

Outlook

The impact of the crisis in the financial markets has led to significantly more difficult market conditions in some of DSM's businesses since the end of Q3. The performance of Nutrition remains strong, as expected. Parts of Materials Sciences and of Base Chemicals and Materials have seen weakening end markets, amplified by customer de-stocking since the end of Q3.

The combined effect of the low availability of credit, a strong decrease in demand in certain end-markets, a strong drop in oil prices, increasing currency volatility and anticipatory behavior in downstream industries, which results in clear de-stocking, is unprecedented. In this context the predictability of short term developments is difficult. However, based on currently available information and barring unforeseen circumstances, DSM's operating profit from continuing operations before exceptional items for the full year is now expected to be around EUR 1,000 million.

Heerlen, 27 October 2008

The Managing Board of Directors

Important dates

Annual Report 2008:	Wednesday, 18 February 2009
Annual General Meeting:	Wednesday, 25 March 2009
Report for the first quarter:	Tuesday 28 April 2009
Report for the second quarter:	Tuesday 28 July 2009
Report for the third quarter:	Tuesday 27 October 2009

DSM – the Life Sciences and Materials Sciences Company

Royal DSM N.V. creates innovative products and services in Life Sciences and Materials Sciences that contribute to the quality of life. DSM's products and services are used globally in a wide range of markets and applications, supporting a healthier, more sustainable and more enjoyable way of life. End markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrics and electronics, life protection and housing. DSM has annual sales of almost EUR 8.8 billion and employs some 23,000 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information: www.dsm.com

For more information

DSM, Corporate Communications
tel.: +31 (45) 5782421
e-mail: media.relations@dsm.com

Investors

DSM, Investor Relations
tel.: +31 (45) 5782864
e-mail: investor.relations@dsm.com

internet: www.dsm.com

Forward-looking statements

This press release contains forward-looking statements. These statements are based on current expectations, estimates and projections of DSM management and information currently available to the company. The statements involve certain risks and uncertainties that are difficult to predict and therefore DSM does not guarantee that its expectations will be realized. Furthermore, DSM has no obligation to update the statements contained in this press release.

The English language version of the press release is leading.

Condensed consolidated statement of income for the third quarter

third quarter 2008			<i>in EUR million</i>	third quarter 2007		
before excep- tional items	excep- tional Items	total		before excep- tional items	excep- tional Items	total
2,392	-	2,392	net sales	2,187	-	2,187
395	-	395	operating profit before depreciation and amortization (EBITDA)	321	-	321
269	-	269	operating profit (EBIT)	214	-	214
2	-	2	operating profit from discontinued operations	4	-	4
267	-	267	operating profit from continuing operations	210	-	210
-26	-	-26	net finance costs	-21	-	-21
-	-	-	share of the profit of associates	-1	-	-1
241	-	241	profit before income taxation expense	188	-	188
-61	-	-61	income tax expense	-47	-	-47
180	-	180	net profit from continuing operations	141	-	141
1	-	1	net profit from discontinued operations	2	-	2
181	-	181	profit for the period	143	-	143
1	-	1	minority interests	-1	-	-1
182	-	182	net profit	142	-	142
182	-	182	net profit	142	-	142
-2	-	-2	dividend on cumulative preference shares	-2	-	-2
180	-	180	net profit used for calculating earnings per share	140	-	140
126	-	126	depreciation and amortization	107	-	107
306	-	306	cash flow	247	-	247
		128	capital expenditure			112
		9	acquisitions			67
			per ordinary share in EUR*:			
1.11	-	1.11	- net earnings, total DSM	0.80	-	0.80
1.10	-	1.10	- net earnings, continuing operations	0.78	-	0.78
1.89	-	1.89	- cash flow	1.41	-	1.41
		162.0	average number of ordinary shares (x million)			175.8
		162.2	number of ordinary shares, end of period (x million)			173.1
		24,052	workforce at end of period			**23,254
		7,395	of which in the Netherlands			**7,219

* After deduction of dividend on cumulative preference shares.

** Year-end 2007.

This quarterly report has not been audited.

Condensed consolidated statement of income January - September

January - September 2008			<i>in EUR million</i>	January - September 2007		
before excep- tional items	excep- tional Items	total		before excep- tional items	excep- tional Items	total
7,206	-	7,206	net sales	6,531	-	6,531
1,116	-	1,116	operating profit plus depreciation and amortization (EBITDA)	947	-1	946
783	-	783	operating profit (EBIT)	633	-151	482
4	-	4	operating profit from discontinued operations	-1	-	-1
779	-	779	operating profit from continuing operations	634	-151	483
-62	-	-62	net finance costs	-53	-	-53
-	-	-	share of the profit of associates	-2	-	-2
717	-	717	profit before income taxation expense	579	-151	428
-180	-	-180	income tax expense	-144	40	-104
537	-	537	net profit from continuing operations	435	-111	324
2	-	2	net profit from discontinued / discontinuing operations	-2	-	-2
539	-	539	profit for the year	433	-111	322
-2	-	-2	minority interests	-5	-	-5
537	-	537	net profit	428	-111	317
537	-	537	net profit	428	-111	317
-7	-	-7	dividend on cumulative preference shares	-7	-	-7
530	-	530	net profit used for calculating earnings per share	421	-111	310
333	-	333	depreciation and amortization	314	150	464
863	-	863	cash flow	735	39	774
		376	capital expenditure			291
		154	acquisitions			93
			per ordinary share in EUR*:			
3.21	-	3.21	- net earnings, total DSM	2.32	-	1.71
3.20	-	3.20	- net earnings, continuing operations	2.33	-	1.72
5.23	-	5.23	- cash flow	4.05	-	4.26
		164.9	average number of ordinary shares (x million)			181.6
		162.2	number of ordinary shares, end of period (x million)			173.1
		24,052	workforce at end of period			**23,254
		7,395	of which in the Netherlands			**7,219

* After deduction of dividend on cumulative preference shares.

** Year-end 2007.

This quarterly report has not been audited.

Consolidated balance sheet

<i>in EUR million</i>	30 September 2008	31 December 2007
intangible assets	1,182	1,037
property, plant and equipment	3,507	3,440
deferred tax assets	342	346
prepaid pension costs *	1,178	1,169
associates	21	20
other financial assets	200	126
	-----	-----
non-current assets	6,430	6,138
inventories	1,890	1,547
trade receivables	1,881	1,452
other receivables	158	235
financial derivatives	66	83
current investments	3	4
cash and cash equivalents	403	369
	-----	-----
current assets	4,401	3,690
assets held for sale	84	-
	-----	-----
total assets	10,915	9,828
<i>in EUR million</i>	30 September 2008	31 December 2007
shareholders' equity	5,433	5,310
minority interests	78	73
	-----	-----
equity	5,511	5,383
deferred tax liabilities	428	344
employee benefits liabilities *	256	273
provisions	175	170
borrowings	1,607	1,560
other non-current liabilities	55	35
	-----	-----
non-current liabilities	2,521	2,382
employee benefits liabilities	17	9
provisions	85	91
borrowings	640	192
financial derivatives	112	42
trade payables	1,402	1,124
other current liabilities	580	605
	-----	-----
current liabilities	2,836	2,063
liabilities held for sale	47	-
	-----	-----
total equity and liabilities	10,915	9,828
capital employed	6,636	5,982
equity / total assets	50%	55%
net debt	1,887	1,338
gearing (net debt / equity plus net debt)	26%	20%
operating working capital (OWC)	2,369	1,875
OWC / 4 x quarterly net sales	25.1%	21.4%

* In accordance with IAS 19, prepaid pension costs and defined benefit liabilities are measured once a year. If current market conditions continue, a significant change in pension assets and liabilities at year-end is to be expected, which will result in a reduction in shareholders' equity.

This quarterly report has not been audited.

Condensed consolidated cash flow statement

<i>in EUR million</i>	January - September	
	2008	2007
<i>Cash and cash equivalents at beginning of period</i>	369	552
<i>Operating activities:</i>		
- net profit plus depreciation and amortization	870	781
- change in operating working capital	-474	-274
- other changes	122	-107
	-----	-----
cash flow from operating activities	518	400
<i>Investing activities:</i>		
- capital expenditure	-387	-259
- acquisitions	-104	-93
- sale of subsidiaries	7	-
- divestments	-	17
- other changes	-70	114
	-----	-----
net cash from investing activities	-554	-221
dividend	-220	-193
net cash from financing activities	270	-316
effects of changes in consolidation and exchange differences	20	-3
	-----	-----
<i>Cash and cash equivalents at end of period</i>	403	219

Condensed statement of changes in shareholders' equity

<i>in EUR million</i>	January - September	
	2008	2007
<i>Balance at beginning of period</i>	5,310	5,784
<i>Changes:</i>		
- net profit	537	317
- exchange differences, net of income tax expenses	56	-98
- dividend	-220	-193
- repurchase of ordinary shares	-250	-508
- proceeds from reissue of ordinary shares	47	40
- other changes	-47	22
	-----	-----
<i>Balance at end of period</i>	5,433	5,364

This quarterly report has not been audited.

Appendix

Examples of DSM's innovation initiatives in Q3 2008:

Nutrition:

- DSM Nutritional Products launched a new formulation of Omega-3 powder for infant nutrition.
- DSM Food Specialties launched Rapidase[®] Expression, a white grape maceration enzyme, developed to assist the production of popular premium white wines.
- Maxiren[®] Gold is the latest preservative-free innovation from DSM Food Specialties developed to maximize cheese manufacturers' production efficiency.
- DSM Food Specialties launched MaxiCurd[™], a new granulated protein hydrolysate range, developed to improve curd strength and to boost cheese yield.
- Panamore[™] is the new alternative to chemical emulsifiers from DSM Food Specialties for the bakery industry, a natural ingredient that leads to increased bread volume, crust appearance and oven spring.

Pharma:

- A major research project initiated by DSM Anti-Infectives, resulted in a breakthrough analysis of the DNA sequence of the fungus *Penicillium chrysogenum*, a major landmark in the 80 year history of penicillin.
- DSM Biologics and Crucell N.V. announced that the high-titer fed-batch process was recently scaled up to 250 liters, successfully achieving 8 grams per liter for an IgG expressed by PER.C6 cells using chemically defined cell culture medium in a single-use bioreactor.

Performance Materials:

- DSM Engineering Plastics launched a new grade of Stanyl[®], to be used in plastic lead chip carriers for high brightness LEDs. Also new Akulon[®] Ultraflow grades for low voltage switchgears were announced.
- DSM Dyneema expanded collaboration with Badinotti Group, the global leader in netting for commercial fishing, to develop and deliver enhanced netting technologies.
- DSM Powder Coating Resins launched Uralac[®] P 780, the first product within its HiTone range for outdoor applications.
- DSM Powder Coating Resins also launched Uralac[®] Corres, a new technology platform for polyester resins for corrosion protective coatings that needs less chemical pre-treatment steps.
- DSM Somos introduced a new software application allowing stereolithography users to create light-weight prototypes having enhanced structural integrity.

Other innovation milestones:

- DSM Nutritional Products received the Innov'Space prize from Salon des Productions Animales, an international trade fair for livestock, for its iCheck[®] Egg product, a kit allowing rapid monitoring of the color of eggs and egg products.
- DSM Food Specialties received the Ringier Technology Innovation Award, a prestigious award within the Food & Beverage industry in China for its product Brewers Clarex[™].
- DSM Composite Resins received an award for best innovation in composite resin materials at the International China Composites Expo in Shanghai (China).
- DSM Biomedical and Caliber Therapeutics announced to partner on the development of a novel drug delivery balloon catheter that can be used to treat vascular diseases such as atherosclerosis.